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TO THE EDITOR
Grouped patterns of pigmented lesions
are infrequent. Here, we analyze a rare
case of segmentally distributed, agmi-
nated nevi characterized by multiple
densely clustered lesions that are con-
fined to a developmental segment.
In fact, most segmental nevi are not
agminated (Happle, 2002) and arise
because of perturbations in the proli-
feration, migration, and differentiation
of embryological precursors, including
melanocytes (Misago et al., 1991; Sun
and Tsao, 2008). The unusual growth
pattern suggests mosaicism, i.e., a con-
dition whereby an organism is com-
posed of two genetically distinct cell
populations due to a post-zygotic muta-
tion (Itin and Burger, 2009). Cutaneous
mosaicism often manifests as lines of
Blaschko, a checkerboard pattern, or a
phylloid (leaf-like) pattern (Happle,
1993).
Recently, mutational analyses of
melanocytic nevi have revealed that
congenital moles, common acquired
nevi, Spitz nevi, and blue nevi are
associated with significant mutation
rates in NRAS (Bauer et al., 2007),
BRAF (Pollock et al., 2003), HRAS (Da
Forno et al., 2009), and GNAQ (Van
Raamsdonk et al., 2009), respectively.
These findings suggest that mutational
activation of specific signaling mole-
cules drives the formation of these nevi.
We thus hypothesized that our patient’s
agminated segmental nevi (ASN) resul-
ted from a mosaic event related to one
of the known RAS effectors.
The patient is a 58-year-old man
who developed numerous grouped
nevi on his right leg shortly after birth.
There was no other significant personal
medical history or family history of
melanoma or dysplastic nevus syn-
drome. On examination of his right
thigh and calf, there was an extensive
band-like cluster of 4100 pigmented
macules, plaques, and papules clini-
cally consistent with junctional, com-
pound, or intradermal nevi (Figure 1a).
Background skin in the area showed no
hypo- or hyperpigmentation. Over mul-
tiple visits, 11 clinically atypical nevi
within the segment were removed
although none had histological features
of melanoma. Pathological evaluation
of the biopsies largely showed intra-
dermal nevi with congenital patterns
(Figure 1b).
This genetic study was approved by
the Research Ethics Board at Dalhousie
University, and was conducted accord-
ing to Declaration of Helsinki Princi-
ples. The patient also gave his written
informed consent. We analyzed the 11Abbreviations: ASN, agminated segmental nevi; CFC, cardio-facio-cutaneous
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ASN and 1 unrelated mole from the
right upper arm, which was excised
independently because of its clinical
atypia. These 12 formalin-fixed, paraf-
fin-embedded specimens were micro-
dissected and screened for mutations in
NRAS exons 2 and 3, and BRAF exons
11 and 15. There were no canonical
activating mutations in NRAS exons or
BRAF exon 11. However, all 11 ASN
harbored the identical BRAFT1799A
transversion (i.e., the BrafV600E altera-
tion) in exon 15. (Primer set: 50-AGAT
CTACTGTTTTCCTTTACTTACTACAC-30
and 50-GGCCAAAAATTTAATCAGTG
GA-30). This mutation was notably
absent in the non-segmental nevus and
in the germline DNA from the patient’s
blood. During the course of Sanger
sequencing, several samples had minor,
but reproducible ‘‘A’’ peaks. To create a
cross-validating platform, we devised a
liquid bead-based assay to more pre-
cisely measure the intratumoral repre-
sentation of the two BRAF alleles
(i.e., wild-type ‘‘T’’ and mutated ‘‘A’’).
(Allele-specific primer for T1799T:
50-CCACTCCATCGAGATTTCT-30; and
T1799A: 50-CCACTCCATCGAGATTT
CA-30). The bead assay substantiated
the presence of the mutation in several
samples (Figure 1c).
There are at least two molecular
models that could explain our patient’s
pigmented lesions. In a ‘‘driver’’ model,
a mutation, such as BrafV600E, occurred
as a mosaic event, and therefore
triggers the transient proliferation of
segmental melanocytes, i.e., mole for-
mation; every ASN should then harbor
the same BrafV600E alteration. Our find-
ing of 100% mutational concordance
among the 11 lesions is certainly
consistent with this ‘‘driver’’ model.
However, a second ‘‘mutator’’ model
can also be considered if the mosaic
event did not occur in the BRAF gene,
but rather, at another locus which then
predisposes the affected melanocyte to
develop activating RAS pathway muta-
tions, including some in BRAF. This
model would have more support if the
ASN were discordant for BRAF status or
harbored distinct changes in BRAF,
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Figure 1. Composite diagram of the clinical, histopathological, and molecular findings of the agminated segmental nevi (ASN). (a) Body chart illustrating
the distribution of the ASN on the right postero-medial thigh and calf, it also illustrates the non-segmental nevus biopsied from the right arm and blood
collected for germline analysis. Clinical photographs of the distribution and close-up comparison between bilateral thighs are provided as insets mapped
from the body chart. (b) Histopathology of the right arm nevus and several of the ASN showing predominantly intradermal nevi with congenital patterns.
Bar¼100 mm. (c) Allelic ratios as determined by the bead assay (mutant (green) vs wild-type (red) signals). The Sanger sequence chromatograms of the
corresponding samples are included. Allelic ratios and chromatograms suggest that all 11 ASN are heterozygous for BRAFT1799A, whereas the germline DNA
and the non-segmental nevus were homozygous wild type. There was a general correlation between Sanger peak ratios; however, some overrepresentation
of the mutant population is noticeable on chromatograms when it is approaching or surpassing 50% composition and may be the result of non-linearity in
the Sanger peak representation. In this assay, a homozygous state was inferred if the minor allelic dose was o10%. Seg, Segmental.
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NRAS or some other gene. If the
‘‘mutator’’ model is in fact correct, 11
independent events would have been
necessary to account for the observed
concordance of BRAFT1799A mutations.
How likely is this latter scenario? Bauer
et al. recently found that 0/32 (0%) of
true congenital nevi and 20/28 (71.4%)
acquired melanocytic nevi ‘‘with a con-
genital pattern’’ harbored BRAFT1799A
mutations. As the mosaic nature of the
ASN is by definition present at birth,
this man’s segmental nevus may be
argued as a variation of a congenital
nevus, and therefore, likely devoid of
BRAF alterations. However, a more
conservative approach would classify
these moles as acquired nevi with a
congenital pattern. In this case, the
probability that independent BRAF
mutagenesis occurred in 11/11 lesions
examined would be estimated at
(0.7111) or 2.3%, a low but certainly
not negligible chance. There are two
additional factors that must be consid-
ered in the calculus. First, the early
onset and segmental nature of the ASN
argues for a mechanistic link between
the populating nevi. In other words, an
analysis of 11 randomly distributed and
arbitrarily selected adult-onset nevi
from a single individual is quite differ-
ent than an analysis from a single group
of ASN. Second, there is a BRAF
distinction between the nevi inside
and the nevus outside of the segment.
In this limited but important specimen,
the formation of the non-segmental
nevus is clearly triggered by a non-
BRAF event. Though our evidence
could be strengthened by a large-scale
sampling of nevi from different sites,
further molecular and statistical pursuits
are not clinically tenable given the
large number of surgeries that have
already transpired.
Recent reports suggest that BRAF
mutations, at least in melanomas, occur
more frequently on intermittently sun-
exposed skin and much less commonly
in non-sun-exposed sites (i.e., mucosal
and acral lentiginous melanomas)
(Maldonado et al., 2003). The segmen-
tal nature of the ASN definitively
eliminates solar participation in the
activation of BRAF. Germline mutations
in BRAF have also been reported in
such conditions as cardio-facio-cuta-
neous (CFC) syndrome, a developmen-
tal disorder with characteristic facial,
cardiac, and ectodermal defects (Nii-
hori et al., 2006) However, most BRAF
mutations in CFC are non-recurrent and
rarely the oncogenic mutations ob-
served in cancers (Rodriguez-Viciana
et al., 2006). Perhaps the Braf signaling
intensity associated with a germline
V600E alteration is incompatible with
life, whereas more tolerable mutations
producing intermediate Braf activity
exist in CFC. If the ‘‘driver’’ model is
correct, the activating event may have
passed a critical susceptibility period in
utero.
In summary, we describe a case of
segmentally arranged, agminated nevi
that exhibit BrafV600E concordance.
Although the evidence strongly sup-
ports a ‘‘driver’’ mosaic model for the
development of these lesions, the high
prevalence of BRAF mutations in gen-
eral raises the possibility of alternative
models.
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